Dewpoint Therapeutics

The discovery of biomolecular #condensates was an astounding breakthrough. A revelation so profound, it completely transformed the understanding of cellular function and organization. Discover how Dewpoint is exploring the relationship between condensate biology and human disease to advance therapies for diseases previously thought undruggable. https://lnkd.in/expN2ZSR #DiscoverDewpoint #biotechnology

We're excited to share that Dewpoint has been awarded a Target ALS grant for the second time! This grant will support our ongoing work to develop innovative treatments for ALS, specifically targeting aberrant TDP-43 condensates to address the inclusions and dysfunction found in nearly all ALS patients. In collaboration with Biospective, this in-kind grant allows us to test our leading compound in a mouse model of slow-progressing ALS—bringing us one step closer to the clinic and, ultimately, to our goal of treating those affected by this devastating disease. At Dewpoint, our approach to drug discovery is unique. We focus on biomolecular condensates—membraneless compartments within the cell that, when dysregulated, contribute to conditions like ALS and other devastating diseases. By targeting these condensates, we’re working to develop first-in-class treatments that address the root causes of diseases of high unmet need. 👉 Learn more at https://lnkd.in/ervBZjDd

Dr. Bede Portz Ph.D. from Dewpoint Therapeutics recently joined the 'Drug Diaries' podcast to discuss the revolutionary potential of condensate biology. In the interview Dr Portz explored how these membrane-less structures are providing new insights into complex cellular processes and innovative approaches to treating diseases including: - The role of condensates in drug discovery - Dewpoint’s focus on targeting the challenging MYC protein in ovarian cancer treatment - The broader implications of condensate science for future therapeutic developments Tune in to gain a deeper understanding of how this cutting-edge research could change the landscape of medicine.: https://lnkd.in/eQT8F_8t

I'm thrilled to share the full episode of my conversation with Dr. Bede Portz Ph.D. on Drug Diaries! This discussion on condensate science is a game-changer. It saved me countless hours of research and is packed with invaluable knowledge and insights, absolutely worth watching if you have any interest in life sciences and drug discovery! A huge thank you to Dr. Bede Portz Ph.D. for his time and the enlightening conversation, Dr. Ameet Nathwani for kindly introducing me to Bede and to Dr. Diana Mitrea for making this insightful episode possible. 🙏 Key highlights: • The revolutionary concept of condensate science • How it's reshaping our understanding of cellular processes • Potential applications in treating diseases like ALS and cancer Want to dive deeper? Comment "please share" below, and I'll send you an exclusive article on condensate science via DM. This article "Exploring Condensate Science: A New Frontier in Treating Ovarian Cancer and ALS," distills the key insights from my in-depth conversation with Dr. Bede Portz Ph.D. into a clear and concise exploration of a field that’s set to change the game in drug discovery. Don't miss this opportunity to expand your understanding of cutting-edge biomedical research. Watch the full episode now! https://lnkd.in/dvFW-ZSY #DrugDiscovery #CondensateScience #BiomedicalResearch #LifeSciences Dewpoint Therapeutics #condensatebiology, #cellularprocesses #MYCprotein, #ovariancancer, #phaseseparation, #biology, #cancer, #chemistry, #science, #oncology

It was a great honor to speak at the Biden Cancer Moonshot Workshop today at the Hubert Humphrey Building in Washington, DC. I had the opportunity to discuss how Dewpoint Therapeutics is leveraging condensate biology and the power of AI to tackle targets once deemed undruggable -an area with immense potential in the fight against cancer. Participating in this pivotal discussion reaffirmed the importance of our work and the need for continued innovation in cancer treatment. Excited to keep pushing the boundaries and contributing to new treatment options for patients.

𝙃𝙤𝙬 𝙘𝙖𝙣 𝙘𝙤𝙣𝙙𝙚𝙣𝙨𝙖𝙩𝙚-𝙙𝙞𝙧𝙚𝙘𝙩𝙚𝙙 𝙙𝙧𝙪𝙜 𝙙𝙞𝙨𝙘𝙤𝙫𝙚𝙧𝙮 𝙩𝙧𝙖𝙣𝙨𝙛𝙤𝙧𝙢 𝙩𝙝𝙚 𝙩𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘 𝙖𝙥𝙥𝙧𝙤𝙖𝙘𝙝 𝙛𝙤𝙧 𝙘𝙤𝙢𝙥𝙡𝙚𝙭 𝙙𝙞𝙨𝙚𝙖𝙨𝙚𝙨? On Monday 19 August at ACS Fall 2024 conference in Denver, Isaac Klein, Chief Scientific Officer of Dewpoint Therapeutics, will present Dewpoint’s platform for condensate target identification and discovery of condensate-modifying drugs. Join Isaac’s talk in person or online, starting at 6:05 PM EDT / 4:05 PM MDT, to learn how this innovative approach is opening new avenues for addressing historically ‘undruggable’ targets and diseases of high unmet need. 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: 𝗦𝗲𝘀𝘀𝗶𝗼𝗻: Modern Phenotypic Drug Discovery & Target Deconvolution of Phenotypic Screens: Advancing Novel Mechanisms of Action Against Historically Intractable Targets 𝗗𝗶𝘃𝗶𝘀𝗶𝗼𝗻: [MEDI] Division of Medicinal Chemistry 🕓 04:00 PM - 07:20 PM EDT, 19 August 2024 📍 Mile High Ballroom 3C (Colorado Convention Center)

Inclusion is one of Dewpoint’s core values, and we believe in empowering our employees to build a culture that’s meaningful to them as individuals. At the recent LEAP HR: Life Sciences East Conference, our own Global & US People Experience Lead Emmanuelle J. shared her perspectives on diversity, equity, inclusion and belonging, how Dewpoint embeds DEI&B into our organization, and the importance of leadership engagement. https://lnkd.in/gQeix47C

The 2024 Neurobiology of Brain Disorders GRC was an exceptional gathering of minds dedicated to unravelling the complexities of neurodegenerative diseases. From presentations to discussions, the exchange of unpublished data, and focus on emerging therapies, this conference was an inspiring reminder of the unified effort required from academia and industry. We were grateful for the opportunity to present our work on c-mods targeting TDP-43 condensates for the treatment of ALS. https://lnkd.in/eru934BQ The ground-breaking insights shared by fellow scientists across various career stages and backgrounds were a true testament to the passion and dedication driving this field. A special thanks to the GRC for organizing such an impactful event. We left feeling invigorated and more motivated than ever to continue our pursuit of solutions for these challenging diseases. Pictured: Dewpoint’s Senior Scientist Gwyneth Welch presenting her poster at the 2024 Neurobiology of Brain Disorders GRC

Dewpoint is honored to be one of the few industry representatives invited to the Biden Cancer Moonshot workshop on 15 August at the Hubert Humphrey building in Washington, DC. This event will provide an opportunity to discuss how AI approaches can address previously undruggable cancer targets (https://lnkd.in/ez6CCqUA). Dewpoint’s Head of Biology, Ann Boija, Ph.D., will present our progress in revolutionizing treatment options for cancers that have been deemed undruggable until now, by leveraging condensate biology and the power of AI. To learn more about Dewpoint’s program targeting beta catenin in colorectal cancer and other solid tumours, read our expert interview https://lnkd.in/e5vuzDJs

This summer, we were pleased to welcome three students to Dewpoint’s Boston office for another successful internship program! Jacob Calka, Cathy Hoang and Mia Russ got real-world experience in the biotech industry, learned about the exciting field of #condensatebiology from scientific leaders on our Biology and Discovery Platform teams, and had some fun along the way! Our team was impressed to hear what they had accomplished during their end of summer presentations, and we look forward to seeing what their bright futures will hold!